Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib

Trevor McKibbin, Wei Zhao, Michael Tagen, Najat C. Daw, Wayne L. Furman, Lisa McGregor, J. Russell Geyer, Jeffrey W. Allen, Clinton F. Stewart

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To investigate associations between germline genetic variations in the epidermal growth factor receptor (EGFR) and toxicity in paediatric patients treated with gefitinib. Patients and methods: Gefitinib treatment and toxicity data from five paediatric clinical trials were combined. EGFR genotypes evaluated included -191C>A, -216G>T, Arg497Lys and intron 1 CA sequence repeat number. The genetic variations were evaluated for associations with grade one or greater rash or diarrhoea during the first course of treatment. Results: The analysis included 110 patients, 60 (55%) with grade one or greater rash and 47 (43%) with grade one or greater diarrhoea. Among patients with the -216 GG (n = 51), GT (n = 41) and TT (n = 16) genotypes, grade one or greater rash occurred in 52.9%, 46.3% and 87.5% of patients (p = 0.003, recessive model), respectively. Diarrhoea occurred in 27.5%, 58.5% and 43.8% of patients with respective GG, GT and TT genotypes (p = 0.004, dominant model). The -191C>A, intron 1 CA repeat number and Arg497Lys genotypes were not significantly associated with either rash or diarrhoea. EGFR -216 and -191 polymorphisms were in linkage disequilibrium (D′ = 0.66, p = 0.01). The haplotype (-191C, -216T) was associated with increased risk for rash (p = 0.049), but was not more predictive of rash than the single -216 polymorphism. Conclusion: These findings indicate that EGFR -216G>T genotype is a predictive marker for the development of skin rash and diarrhoea in paediatric patients treated with gefitinib. Continued investigation of relationships between germline EGFR polymorphisms and the efficacy of EGFR inhibitors in paediatric patients is warranted.

Original languageEnglish (US)
Pages (from-to)2045-2051
Number of pages7
JournalEuropean Journal of Cancer
Volume46
Issue number11
DOIs
StatePublished - Jul 1 2010

Fingerprint

Epidermal Growth Factor Receptor
Exanthema
Pediatrics
Diarrhea
Genotype
Introns
gefitinib
Linkage Disequilibrium
Haplotypes
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

McKibbin, Trevor ; Zhao, Wei ; Tagen, Michael ; Daw, Najat C. ; Furman, Wayne L. ; McGregor, Lisa ; Geyer, J. Russell ; Allen, Jeffrey W. ; Stewart, Clinton F. / Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. In: European Journal of Cancer. 2010 ; Vol. 46, No. 11. pp. 2045-2051.
@article{904c609c5cec41ed80a890086e5ed71d,
title = "Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib",
abstract = "Purpose: To investigate associations between germline genetic variations in the epidermal growth factor receptor (EGFR) and toxicity in paediatric patients treated with gefitinib. Patients and methods: Gefitinib treatment and toxicity data from five paediatric clinical trials were combined. EGFR genotypes evaluated included -191C>A, -216G>T, Arg497Lys and intron 1 CA sequence repeat number. The genetic variations were evaluated for associations with grade one or greater rash or diarrhoea during the first course of treatment. Results: The analysis included 110 patients, 60 (55{\%}) with grade one or greater rash and 47 (43{\%}) with grade one or greater diarrhoea. Among patients with the -216 GG (n = 51), GT (n = 41) and TT (n = 16) genotypes, grade one or greater rash occurred in 52.9{\%}, 46.3{\%} and 87.5{\%} of patients (p = 0.003, recessive model), respectively. Diarrhoea occurred in 27.5{\%}, 58.5{\%} and 43.8{\%} of patients with respective GG, GT and TT genotypes (p = 0.004, dominant model). The -191C>A, intron 1 CA repeat number and Arg497Lys genotypes were not significantly associated with either rash or diarrhoea. EGFR -216 and -191 polymorphisms were in linkage disequilibrium (D′ = 0.66, p = 0.01). The haplotype (-191C, -216T) was associated with increased risk for rash (p = 0.049), but was not more predictive of rash than the single -216 polymorphism. Conclusion: These findings indicate that EGFR -216G>T genotype is a predictive marker for the development of skin rash and diarrhoea in paediatric patients treated with gefitinib. Continued investigation of relationships between germline EGFR polymorphisms and the efficacy of EGFR inhibitors in paediatric patients is warranted.",
author = "Trevor McKibbin and Wei Zhao and Michael Tagen and Daw, {Najat C.} and Furman, {Wayne L.} and Lisa McGregor and Geyer, {J. Russell} and Allen, {Jeffrey W.} and Stewart, {Clinton F.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.ejca.2010.05.007",
language = "English (US)",
volume = "46",
pages = "2045--2051",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "11",

}

McKibbin, T, Zhao, W, Tagen, M, Daw, NC, Furman, WL, McGregor, L, Geyer, JR, Allen, JW & Stewart, CF 2010, 'Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib', European Journal of Cancer, vol. 46, no. 11, pp. 2045-2051. https://doi.org/10.1016/j.ejca.2010.05.007

Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. / McKibbin, Trevor; Zhao, Wei; Tagen, Michael; Daw, Najat C.; Furman, Wayne L.; McGregor, Lisa; Geyer, J. Russell; Allen, Jeffrey W.; Stewart, Clinton F.

In: European Journal of Cancer, Vol. 46, No. 11, 01.07.2010, p. 2045-2051.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib

AU - McKibbin, Trevor

AU - Zhao, Wei

AU - Tagen, Michael

AU - Daw, Najat C.

AU - Furman, Wayne L.

AU - McGregor, Lisa

AU - Geyer, J. Russell

AU - Allen, Jeffrey W.

AU - Stewart, Clinton F.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Purpose: To investigate associations between germline genetic variations in the epidermal growth factor receptor (EGFR) and toxicity in paediatric patients treated with gefitinib. Patients and methods: Gefitinib treatment and toxicity data from five paediatric clinical trials were combined. EGFR genotypes evaluated included -191C>A, -216G>T, Arg497Lys and intron 1 CA sequence repeat number. The genetic variations were evaluated for associations with grade one or greater rash or diarrhoea during the first course of treatment. Results: The analysis included 110 patients, 60 (55%) with grade one or greater rash and 47 (43%) with grade one or greater diarrhoea. Among patients with the -216 GG (n = 51), GT (n = 41) and TT (n = 16) genotypes, grade one or greater rash occurred in 52.9%, 46.3% and 87.5% of patients (p = 0.003, recessive model), respectively. Diarrhoea occurred in 27.5%, 58.5% and 43.8% of patients with respective GG, GT and TT genotypes (p = 0.004, dominant model). The -191C>A, intron 1 CA repeat number and Arg497Lys genotypes were not significantly associated with either rash or diarrhoea. EGFR -216 and -191 polymorphisms were in linkage disequilibrium (D′ = 0.66, p = 0.01). The haplotype (-191C, -216T) was associated with increased risk for rash (p = 0.049), but was not more predictive of rash than the single -216 polymorphism. Conclusion: These findings indicate that EGFR -216G>T genotype is a predictive marker for the development of skin rash and diarrhoea in paediatric patients treated with gefitinib. Continued investigation of relationships between germline EGFR polymorphisms and the efficacy of EGFR inhibitors in paediatric patients is warranted.

AB - Purpose: To investigate associations between germline genetic variations in the epidermal growth factor receptor (EGFR) and toxicity in paediatric patients treated with gefitinib. Patients and methods: Gefitinib treatment and toxicity data from five paediatric clinical trials were combined. EGFR genotypes evaluated included -191C>A, -216G>T, Arg497Lys and intron 1 CA sequence repeat number. The genetic variations were evaluated for associations with grade one or greater rash or diarrhoea during the first course of treatment. Results: The analysis included 110 patients, 60 (55%) with grade one or greater rash and 47 (43%) with grade one or greater diarrhoea. Among patients with the -216 GG (n = 51), GT (n = 41) and TT (n = 16) genotypes, grade one or greater rash occurred in 52.9%, 46.3% and 87.5% of patients (p = 0.003, recessive model), respectively. Diarrhoea occurred in 27.5%, 58.5% and 43.8% of patients with respective GG, GT and TT genotypes (p = 0.004, dominant model). The -191C>A, intron 1 CA repeat number and Arg497Lys genotypes were not significantly associated with either rash or diarrhoea. EGFR -216 and -191 polymorphisms were in linkage disequilibrium (D′ = 0.66, p = 0.01). The haplotype (-191C, -216T) was associated with increased risk for rash (p = 0.049), but was not more predictive of rash than the single -216 polymorphism. Conclusion: These findings indicate that EGFR -216G>T genotype is a predictive marker for the development of skin rash and diarrhoea in paediatric patients treated with gefitinib. Continued investigation of relationships between germline EGFR polymorphisms and the efficacy of EGFR inhibitors in paediatric patients is warranted.

UR - http://www.scopus.com/inward/record.url?scp=77954218609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954218609&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2010.05.007

DO - 10.1016/j.ejca.2010.05.007

M3 - Article

C2 - 20621735

AN - SCOPUS:77954218609

VL - 46

SP - 2045

EP - 2051

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 11

ER -